UC, Berkeley appeals to Federal Circuit in CRISPR patent clash

The University of California (UC), Berkeley and the University of Vienna have appealed against the Patent Trial and Appeal Board's (PTAB) decision in the dispute over CRISPR technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.

Americas

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

UC, Berkeley appeals to Federal Circuit in CRISPR patent clash

More on this story

Editor's picks

Editor's picks

More features